Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

Orchard Therapeutics plc (NASDAQ:ORTX) Receives Average Recommendation of "Hold" from Brokerages

Financial News Live ·  {{timeTz}}

Shares of Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) have received a consensus rating of "Hold" from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $7.75.

Separately, Barclays cut their price target on shares of Orchard Therapeutics from $6.00 to $4.00 in a research note on Friday, May 13th.

Get Orchard Therapeutics alerts:

Institutional Trading of Orchard Therapeutics

A number of institutional investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in Orchard Therapeutics in the 4th quarter worth approximately $858,000. Harbor Capital Advisors Inc. purchased a new position in Orchard Therapeutics during the 4th quarter valued at $364,000. BlackRock Inc. raised its holdings in Orchard Therapeutics by 19.9% in the 1st quarter. BlackRock Inc. now owns 749,990 shares of the company's stock worth $534,000 after purchasing an additional 124,478 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Orchard Therapeutics in the 4th quarter worth about $141,000. Finally, Bank of America Corp DE boosted its stake in shares of Orchard Therapeutics by 130.8% during the 1st quarter. Bank of America Corp DE now owns 95,749 shares of the company's stock valued at $68,000 after purchasing an additional 54,270 shares in the last quarter. 56.47% of the stock is currently owned by hedge funds and other institutional investors.

Orchard Therapeutics Stock Performance

ORTX traded up $0.02 on Wednesday, hitting $0.61. The company's stock had a trading volume of 600 shares, compared to its average volume of 741,904. Orchard Therapeutics has a 12 month low of $0.41 and a 12 month high of $3.18. The firm has a market cap of $77.14 million, a P/E ratio of -0.44 and a beta of 0.81. The company has a quick ratio of 4.24, a current ratio of 4.24 and a debt-to-equity ratio of 0.19. The company's 50 day simple moving average is $0.57 and its 200-day simple moving average is $0.69.

Orchard Therapeutics (NASDAQ:ORTX – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.10). Orchard Therapeutics had a negative return on equity of 86.92% and a negative net margin of 1,452.46%. The company had revenue of $5.52 million during the quarter, compared to the consensus estimate of $4.97 million. Analysts forecast that Orchard Therapeutics will post -0.95 EPS for the current year.

Orchard Therapeutics Company Profile

(Get Rating)

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.

Recommended Stories

  • Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
  • Workhorse Group Is Ready To Get Back On The Horse
  • A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
  • Are 3M, Honeywell, GE Buys After Quarterly Reports?
  • Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
  • This Defense Stock Has Bullish Fundamentals AND Technicals

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.